Search Results - "Brennan, Barbara J."

Effect of peginterferon alfa‐2a (40KD) on cytochrome P450 isoenzyme activity by Brennan, Barbara J., Xu, Zhi‐Xin, Grippo, Joseph F.

“…Aim Pegylated interferon‐based therapy is recommended for treatment of hepatitis C virus (HCV) infection. Because interferons are known to down‐regulate…”
Get full text

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir by Brennan, Barbara J., Poirier, Agnès, Moreira, Sebastian, Morcos, Peter N., Goelzer, Petra, Portmann, Renée, Asthappan, Jiney, Funk, Christoph, Smith, Patrick F.

“…Background and Objectives Understanding transmembrane transport provides a more complete understanding of the pharmacokinetics of a drug and mechanistic…”
Get full text

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders by GANE, Edward J, ROUZIER, Régine, KULKARNI, Rohit, YING ZHANG, SMITH, Patrick, YETZER, Ellen S, SHULMAN, Nancy S, WIERCINSKA-DRAPALO, Alicja, LARREY, Dominique G, MORCOS, Peter N, BRENNAN, Barbara J, LE POGAM, Sophie, NAJERA, Isabel, PETRIC, Rosemary, TRAN, Jonathan Q

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers by BRENNAN, Barbara J, DAVIES, Brian, CIRRINCIONE-DALL, Georgina, MORCOS, Peter N, BERYOZKINA, Anna, CHAPPEY, Colombe, ACEVES BALDO, Pau, LENNON-CHRIMES, Sian, RAYNER, Craig R

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin by Brennan, Barbara J., Moreira, Sebastian A., Morcos, Peter N., Navarro, Mercidita T., Asthappan, Jiney, Goelzer, Petra, Weigl, Paul, Smith, Patrick F.

“…Background Danoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease, which is currently in development in combination…”
Get full text

Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study by Brennan, Barbara J., PharmD, Xu, Zhi-Xin, MD, PhD, Grippo, Joseph F., PhD

“…Abstract Background Interferon (IFN)-based therapy is the recommended treatment for hepatitis C virus. Because pegylated IFN (PEG-IFN) alfa-2a is administered…”
Get full text

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study by Casanova, Michela, Bautista, Francisco, Campbell-Hewson, Quentin, Makin, Guy, Marshall, Lynley V., Verschuur, Arnauld C., Cañete Nieto, Adela, Corradini, Nadège, Ploeger, Bart A., Brennan, Barbara J., Mueller, Udo, Zebger-Gong, Hong, Chung, John W., Geoerger, Birgit

“…Abstract Purpose: This phase Ib study defined the safety, MTD, and recommended phase II dose (RP2D) of regorafenib combined with vincristine and irinotecan…”
Get full text

Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs by Liu, Wenying Angela, Yu, Li, Morcos, Peter N., Mercier, Francois, Brennan, Barbara J.

“…Purpose To assess the translational value of anticancer preclinical models, we retrospectively investigated the relationships between preclinical data and…”
Get full text

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study by Fakih, Marwan, Raghav, Kanwal Pratap Singh, Chang, David Z., Larson, Tim, Cohn, Allen L., Huyck, Timothy K., Cosgrove, David, Fiorillo, Joseph A., Tam, Rachel, D'Adamo, David, Sharma, Neelesh, Brennan, Barbara J., Wang, Ying A., Coppieters, Sabine, Zebger-Gong, Hong, Weispfenning, Anke, Seidel, Henrik, Ploeger, Bart A., Mueller, Udo, Oliveira, Carolina Soares Viana de, Paulson, Andrew Scott

“…Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal…”
Get full text

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa‐2a dosing regimen for children with hepatitis C by Brennan, Barbara J., Lemenuel‐Diot, Annabelle, Snoeck, Eric, McKenna, Michael, Solsky, Jonathan, Wat, Cynthia, Mallalieu, Navita L.

“…Aim The aim of the study was to simplify the dosing regimen of peginterferon alfa‐2a in paediatric patients with chronic hepatitis C. Methods A population…”
Get full text

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail by Morcos, Peter N., Chang, Linda, Kulkarni, Rohit, Giraudon, Mylene, Shulman, Nancy, Brennan, Barbara J., Smith, Patrick F., Tran, Jonathan Q.

“…Purpose The aim of this study was to evaluate the effects of danoprevir in combination with low-dose ritonavir (danoprevir/r) and placebo plus low-dose…”
Get full text

Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis by Kao, Jia-Horng, Tung, Shui-Yi, Lee, Younjae, Thongsawat, Satawat, Tanwandee, Tawesak, Sheen, I.-Shyan, Wu, Jinzi J., Li, Hui, Brennan, Barbara J., Zhou, Julian, Le Pogam, Sophie, Najera, Isabel, Thommes, James A., Hill, George

“…Background and Aim Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed‐dose…”
Get full text

Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment by Gibiansky, Leonid, Giraudon, Mylène, Rayner, Craig R., Brennan, Barbara J., Subramoney, Vishak, Robson, Richard, Kamal, Mohamed A.

“…This work characterizes the pharmacokinetics (PK) of oseltamivir phosphate (OP) and its active metabolite, oseltamivir carboxylate (OC), and investigates…”
Get full text

Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers by Morcos, Peter N., Moreira, Sebastian A., Navarro, Mercidita T., Bech, Núria, Quatkemeyer, Amanda, Smith, Patrick F., Brennan, Barbara J.

“…Objectives To evaluate the effect of a low‐ and high‐fat meal and co‐administration of ranitidine or omeprazole on the pharmacokinetics of ritonavir‐boosted…”
Get full text

Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy by Moreira, Sebastian A., Morcos, Peter N., Navarro, Mercidita T., Bech, Nuria, Smith, Patrick F., Brennan, Barbara J.

“…Study Objective To investigate the steady‐state pharmacokinetics of methadone when coadministered with ritonavir‐boosted danoprevir (DNVr). Design Open‐label,…”
Get full text

Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS by Morcos, Peter N, Leong, Ruby, Thommes, James A, DePamphilis, Jean, Grippo, Joseph F, Brennan, Barbara J

“…PROGRESS randomized chronic hepatitis C genotype 1 patients with a baseline viral load ≥400,000 IU/mL weighing ≥85 kg to regimens of 180 μg/week for 48 weeks…”
Get more information

Two-way interaction study using ritonavir-boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects by MORCOS, Peter N, CHANG, Linda, NAVARRO, Mercidita, CHUNG, Diana, SMITH, Patrick F, BRENNAN, Barbara J, TRAN, Jonathan Q

Get full text

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis by Gane, Edward J., Rouzier, Régine, Hassanein, Tarek, Stedman, Catherine A., Mazur, Wlodzimierz, Kupcova, Viera, Le Pogam, Sophie, Eng, Simon, Voulgari, Athina, Morcos, Peter N., Brennan, Barbara J., Scalori, Astrid, Thommes, James

“…Background and aim Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. Methods An…”
Get full text

Pharmacokinetics and Safety of Coadministered Oseltamivir and Rimantadine in Healthy Volunteers: An Open-Label, Multiple-Dose, Randomized, Crossover Study by Cirrincione-Dall, Georgina, Brennan, Barbara J., Ballester-Sanchis, Rosa M., Navarro, Mercidita T., Davies, Brian E.

“…Preclinical data suggest increased antiviral activity and less viral resistance when neuraminidase inhibitors and adamantanes are used in combination to…”
Get full text

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible by Reddy, Micaela B., Connor, Alyson, Brennan, Barbara J., Morcos, Peter N., Zhou, Amy, McLawhon, Pamela, Fretland, Adrian, Evans, Philip, Smith, Patrick, Tran, Jonathan Q.

“…ABSTRACT Danoprevir, a potent, selective inhibitor of HCV NS3/4A protease, has a short half‐life in humans. Therefore, the feasibility of a controlled release…”
Get full text